Subject: 7/8 CFS cases and 2/17 controls were positive for XMRV using Next Gener

[Guest guest]

Subject: 7/8 CFS cases and 2/17 controls were positive for XMRV using Next

Generation Sequencing (NGS) technology

The Cheney Clinic

Changing status of XMRV / HGRV research

December 5th, 2011,

published in Public Relations

There is still no consensus in either direction for the

existence or non-existence of XMRV associated with CFS

cases.

Studies out of Europe (Belgium and Germany) and the US

(Cornell) as well as elsewhere which are separate from

WPI, FDA and NCI are demonstrating evidence that

cannot be due to a mouse contaminant for XMRV

association with CFS.

The strongest supportive study to date was reported by Dr.

Strayer out of Hemispherex Inc, (Philadephia, PA)

at IACFS/ME in Ottawa and showed that 7/8 CFS cases

and 2/17 controls were positive for XMRV using Next

Generation Sequencing (NGS) technology available at

Roche Labs in Germany.

NGS is not susceptible to mouse contamination and

demonstrates that XMRV is in fact integrated into human

DNA which means it is a human virus.

The Science (Lombardi et al, 2009) study still stands as

the best evidence that this virus is transmissible from cell

to cell and the studies out of WPI and Belgium

demonstrate an immune response (antibodies) to XMRV

and a cytokine profile (WPI) that suggests it is pathologic.

I expect that Next Generation Sequencing or NGS, which

does not have the flaws of PCR technology in evaluating a

poorly understood human virus(es), will be the best way

forward to a consensus as to the question of association

of CFS with XMRV/HGRV.

This preliminary report out of Germany using NGS as well

as human immune response data supports the

association of XMRV with CFS, despite the flaws exposed

in the current primary PCR technology used to define this

scientific debate which appears very messy and

excessively bio-political to date.